Anastasiya V. Sholokhova

Anastasiya V. Sholokhova

Auto-generated profile, based on publicly available information

Anastasiya V. Sholokhova

Republican Clinical Perinatal Center

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
VAV.R. Amirova
V.R. Amirova
AGA.A. Greshilov
A.A. Greshilov
ASA.V. Sholokhova
A.V. Sholokhova
Preterm infants born before the 35th week of gestation are at high risk of severe respiratory syncytial virus (RSV) infection. Passive immunoprophylaxis with palivizumab, a monoclonal antibody against RSV, is currently recognized as the most effective measure to prevent RSV infection. The objective of the study was to evaluate the efficacy of prophylactic use of palivizumab in premature infants at high risk of severe RSVI. Patients and methods. A single-center retrospective cohort study conducted on the basis of the Catamnesis Cabinet of the Republican Clinical Perinatal Center (Ufa) included 516 premature children with gestational age less than 35 weeks who reached the age of 1 year of life from April 2020 to April 2022. 250 children were included in the "immunization+" group, and 266 children were included in the "immunization-" group. In both groups, the proportion of children who went to the outpatient clinic for acute respiratory infection (ARI) and the proportion of children hospitalized for lower respiratory tract infection (LRTI) were determined. Results. Among the immunized, the proportion of children presenting to the outpatient clinic for ARI was lower than among the non-immunized, 63.6% and 82.0%, respectively (p < 0.001; OR 0.77; 95% CI 0.69-0.86). There was no statistically significant reduction in the rate of hospitalization of preterm infants due to LRTI overall. However, the proportion of children hospitalized for bronchitis was lower among the immunized than among the non-immunized, 24.0 and 31.6%, respectively (p = 0.045; HR 0.74; 95% CI 0.55-0.99). The greatest effect of palivizumab immunization was observed in children born at 32 weeks' gestation or less who received 3-5 injections of the drug. Conclusion. This study demonstrated the efficacy of immunoprophylaxis with palivizumab in premature infants of the first year of life from the high-risk group of severe RSVI. Key words: respiratory syncytial virus, acute respiratory infection, hospitalization, premature infants, high-risk group, immunoprophylaxis, palivizumab

6 June 2023 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
VAVictoria R. Amirova
Victoria R. Amirova
AGArsentiy A. Greshilov
Arsentiy A. Greshilov
ASAnastasiya V. Sholokhova
Anastasiya V. Sholokhova
ШВШолохова Анастасия Викторовна
Шолохова Анастасия Викторовна
Background. Palivizumab has been successfully used in many countries worldwide to prevent respiratory syncytial infection in children at risk of severe infection. Despite the drug use experience in some regions of the Russian Federation, evidence on the outcomes of specific immunoprophylaxis in children from risk groups is scarce. Aim. To assess the results of the regional immunoprophylaxis program for children at high risk of severe respiratory syncytial virus infection (RSVI) with palivizumab in the Republic of Bashkortostan. Materials and methods. A single-center retrospective cohort study was conducted at the Catamnesis Cabinet of the Republican Clinical Perinatal Center, Ufa. A total of 516 preterm infants born before the full 35 weeks of gestation and who reached the age of 1 year of life between April 2020 and April 2022 were included in the study. Group 1 (palivizumab+) included 250 infants who received at least one immunization against RSVI at a dose of 15 mg/kg; Group 2 (palivizumab-) included 266 infants without immunization. In both groups, the percentage of children admitted to the clinic for acute respiratory infections and hospitalized for lower respiratory infections was determined. Results. It was found that children born at a gestational age of 32 weeks had immunoprophylaxis more often than children born at a gestational age of 3235 weeks (58.1% vs 37.2%; p0.001); also, they more often received 35 injections of palivizumab (32.9% vs 17.9%; p=0.018). The proportion of children who were admitted to the clinic for ARI was lower among those immunized than among those not immunized: 63.6% vs 82.0% (p0.001; relative risk RR 0.77, 95% confidence interval CI 0.690.86). Of children who received 12 injections of palivizumab, 70.2% sought medical care for acute respiratory infections versus 53.3% of children who received 35 injections (p0.001; RR 1.51, 95% CI 1.151.98). Among the immunized infants, the percentage of children admitted to the hospital for bronchitis was significantly lower: 24.0% vs 31.6% (p=0.045; RR 0.74, 95% CI 0.550.99). The most significant effect of palivizumab was demonstrated in children born at the gestational age of 32 weeks or less, who received 35 injections of the drug. Conclusion. The study demonstrated the effectiveness of the regional RSVI immunoprophylaxis program with palivizumab in children in the first year of life at risk for severe infection in the Republic of Bashkortostan.